Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment

Published:2017-06 Issue:6 Volume:39 Page:101042831771103
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumour Biol.

Author:

Lin Ying¹²,Wu Zheng³,Zhang Jian¹²,Hu Xichun¹²,Wang Zhonghua¹²,Wang Biyun¹²,Cao Jun¹²,Wang Leiping¹²

Affiliation:

1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

3. Department of Radiotherapy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Publisher

IOS Press

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1010428317711033

Reference32 articles.

1. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

2. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

3. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy

4. Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis;Radiology and Oncology;2023-11-30

2. Cubic upconversion nanoparticles used as the theranostic system for the treatment and diagnosis of angiogenesis-related diseases;Materials Today Advances;2022-12

3. The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review;Translational Cancer Research;2022-11

4. Effects of Apatinib Mesylate Monotherapy on the Incidence of Adverse Reactions and Immune Function in Patients with Breast Cancer after Radical Mastectomy;Evidence-Based Complementary and Alternative Medicine;2022-08-10

5. Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis;Frontiers in Oncology;2022-08-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3